PRVB [NASD]
Provention Bio, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own15.68% Shs Outstand64.72M Perf Week27.44%
Market Cap430.60M Forward P/E- EPS next Y-1.53 Insider Trans0.00% Shs Float43.39M Perf Month26.01%
Income-104.50M PEG- EPS next Q-0.40 Inst Own31.00% Short Float7.87% Perf Quarter42.64%
Sales2.70M P/S159.48 EPS this Y3.50% Inst Trans1.87% Short Ratio5.36 Perf Half Y-15.99%
Book/sh1.22 P/B4.61 EPS next Y35.20% ROA-80.30% Target Price14.14 Perf Year-14.33%
Cash/sh1.10 P/C5.10 EPS next 5Y- ROE-100.10% 52W Range3.18 - 8.04 Perf YTD0.00%
Dividend- P/FCF- EPS past 5Y- ROI-103.50% 52W High-30.78% Beta2.46
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low74.73% ATR0.31
Employees82 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)72.61 Volatility7.06% 6.66%
OptionableYes Debt/Eq0.00 EPS Q/Q0.20% Profit Margin- Rel Volume0.69 Prev Close5.62
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume636.25K Price5.57
Recom1.90 SMA2028.92% SMA5033.10% SMA2002.29% Volume164,678 Change-0.98%
Nov-23-21Upgrade SMBC Nikko Neutral → Outperform
Apr-09-21Reiterated SVB Leerink Outperform $26 → $16
Apr-09-21Downgrade RBC Capital Mkts Outperform → Sector Perform $27 → $25
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Aug-12-22 10:53AM  
Aug-04-22 10:25AM  
07:00AM  
Aug-02-22 04:05PM  
Jul-28-22 07:30AM  
Jul-26-22 10:07AM  
Jul-07-22 07:28PM  
Jul-05-22 04:01PM  
Jun-30-22 04:01PM  
Jun-23-22 10:58AM  
Jun-03-22 07:35AM  
07:30AM  
07:00AM  
May-30-22 07:12AM  
May-19-22 11:23AM  
May-12-22 07:30AM  
May-05-22 08:25AM  
07:00AM  
May-03-22 07:30AM  
Apr-29-22 01:29PM  
Apr-28-22 07:30AM  
Apr-13-22 04:20AM  
Apr-04-22 04:05PM  
Mar-28-22 03:27PM  
07:30AM  
Mar-04-22 04:05PM  
Mar-03-22 07:30AM  
Feb-26-22 07:14AM  
Feb-24-22 08:25AM  
07:00AM  
Feb-22-22 01:59PM  
07:30AM  
Feb-17-22 04:05PM  
Feb-10-22 07:30AM  
Feb-04-22 04:05PM  
Jan-31-22 04:13PM  
Jan-28-22 12:04PM  
07:55AM  
Jan-27-22 04:05PM  
Jan-21-22 06:57AM  
Jan-20-22 04:05PM  
Jan-07-22 07:30AM  
Jan-06-22 07:30AM  
Dec-20-21 07:34AM  
Dec-02-21 07:30AM  
Nov-29-21 08:02AM  
Nov-25-21 10:00AM  
Nov-22-21 07:30AM  
Nov-17-21 07:30AM  
Nov-09-21 12:00PM  
10:38AM  
08:00AM  
Nov-06-21 01:00PM  
Nov-05-21 04:30PM  
Nov-04-21 08:35AM  
07:05AM  
07:00AM  
Oct-28-21 07:30AM  
Oct-26-21 01:43PM  
07:30AM  
Oct-21-21 09:32PM  
Sep-23-21 07:30AM  
Sep-16-21 07:30AM  
Sep-13-21 07:30AM  
Sep-10-21 12:19PM  
Aug-30-21 10:34AM  
Aug-09-21 08:37PM  
Aug-06-21 07:00PM  
02:04PM  
Aug-05-21 08:45AM  
07:00AM  
Jul-29-21 07:00AM  
Jul-20-21 02:20PM  
01:35PM  
10:40AM  
10:03AM  
09:36AM  
Jul-19-21 03:51PM  
03:00PM  
02:30PM  
12:21PM  
10:40AM  
10:15AM  
10:00AM  
10:00AM  
09:00AM  
05:40AM  
12:50AM  
Jul-18-21 11:49AM  
09:30AM  
09:00AM  
Jul-16-21 07:30PM  
03:53PM  
02:10PM  
01:05PM  
11:35AM  
11:25AM  
10:35AM  
10:11AM  
06:52AM  
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ramos EleanorChief Medical OfficerDec 03Buy6.495,20133,76570,000Dec 06 09:28 PM
Palmer AshleighDirector and CEONov 30Buy6.663,75024,9902,570,050Dec 01 09:21 PM
Leon FranciscoChief Scientific OfficerNov 24Buy7.245,55040,1882,573,000Nov 29 05:15 PM